DE69212671T2 - Rekombinante Antikörper spezifisch für einen Wachstumsfaktor-Rezeptor - Google Patents

Rekombinante Antikörper spezifisch für einen Wachstumsfaktor-Rezeptor

Info

Publication number
DE69212671T2
DE69212671T2 DE69212671T DE69212671T DE69212671T2 DE 69212671 T2 DE69212671 T2 DE 69212671T2 DE 69212671 T DE69212671 T DE 69212671T DE 69212671 T DE69212671 T DE 69212671T DE 69212671 T2 DE69212671 T2 DE 69212671T2
Authority
DE
Germany
Prior art keywords
chain variable
variable domain
dna
recombinant antibodies
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69212671T
Other languages
English (en)
Other versions
DE69212671D1 (de
Inventor
Winfried Stephan Dr Wels
Nancy E Dr Hynes
Ina-Maria Harwerth
Bernd Dr Groner
Norman Dr Hardman
Markus Zwickl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of DE69212671D1 publication Critical patent/DE69212671D1/de
Application granted granted Critical
Publication of DE69212671T2 publication Critical patent/DE69212671T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69212671T 1991-02-05 1992-01-27 Rekombinante Antikörper spezifisch für einen Wachstumsfaktor-Rezeptor Expired - Fee Related DE69212671T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91810079 1991-02-05

Publications (2)

Publication Number Publication Date
DE69212671D1 DE69212671D1 (de) 1996-09-19
DE69212671T2 true DE69212671T2 (de) 1997-03-13

Family

ID=8208816

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69212671T Expired - Fee Related DE69212671T2 (de) 1991-02-05 1992-01-27 Rekombinante Antikörper spezifisch für einen Wachstumsfaktor-Rezeptor

Country Status (10)

Country Link
EP (1) EP0502812B1 (de)
JP (1) JP3415171B2 (de)
AT (1) ATE141329T1 (de)
AU (1) AU662311B2 (de)
CA (1) CA2060544C (de)
DE (1) DE69212671T2 (de)
DK (1) DK0502812T3 (de)
ES (1) ES2091438T3 (de)
GR (1) GR3020809T3 (de)
IE (1) IE72959B1 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741444B2 (en) 2002-07-04 2010-06-22 Patrys Limited Neoplasm specific antibodies and uses thereof
US8124080B2 (en) 2003-11-14 2012-02-28 Patrys Limited Human monoclonal antibody having fat-reducing effect
US8562995B2 (en) 2003-03-14 2013-10-22 Patrys Limited Neoplasm specific antibodies and uses thereof
US8741296B2 (en) 2003-11-14 2014-06-03 Patrys Limited Adenocarcinoma specific antibody SAM-6, and uses thereof

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016185A2 (en) * 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
CA2157767A1 (en) * 1993-03-09 1994-09-15 Elaine M. Brate Genetically engineered enzymes and their conjugates for diagnostic assays
IT1264083B1 (it) * 1993-12-10 1996-09-10 Enea Ente Nuove Tec Procedimento per la produzione in piante di anticorpi ingegnerizzati, anticorpi prodotti e loro uso in diagnosi e terapia.
AU694222B2 (en) 1994-05-02 1998-07-16 Bernd Groner Bifunctional protein, preparation and use
EP0739984A1 (de) * 1995-04-26 1996-10-30 San Tumorforschungs-Gmbh Bivalente Polypeptiden die mindestens zwei Bereichen enthalten
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方
PT1516628E (pt) * 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2246429C (en) * 1996-03-27 2007-07-24 Genentech, Inc. Erbb3 antibodies
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
DE19735105A1 (de) * 1997-08-13 1999-03-04 Univ Albert Ludwigs Freiburg Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen
PL365999A1 (en) 1999-05-14 2005-01-24 Imclone Systems Incorporated Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
KR20130056201A (ko) 2000-05-19 2013-05-29 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
WO2006083355A2 (en) 2004-11-19 2006-08-10 Cornell Research Foundation, Inc. Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
AU2005325200A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of HER antibodies
JP2008531576A (ja) 2005-02-23 2008-08-14 ジェネンテック・インコーポレーテッド Ｈｅｒ二量体化阻害剤を使用した、ガン患者における疾患の進行までの期間または生存の延長
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
NZ578824A (en) 2007-03-02 2012-03-30 Genentech Inc Predicting response to a her dimerisation inhibitor based on low her3 expression
US20100298156A1 (en) 2007-06-08 2010-11-25 Si Tuen Lee-Hoeflich Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
JP2012507299A (ja) 2008-10-31 2012-03-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｇｈｔ標的分子およびその使用
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
CN102892779B (zh) 2010-02-18 2016-12-21 基因泰克公司 神经调节蛋白拮抗剂及其在治疗癌症中的用途
EP2536432B1 (de) 2010-02-19 2018-08-08 Cornell University Verfahren zur behandlung demyelinisierender autoimmunerkrankungen und anderer autoimmun- oder entzündungserkrankungen
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
MX2014001766A (es) 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
RU2019103083A (ru) 2011-11-30 2019-03-22 Дженентек, Инк. МУТАЦИИ ErbB3 ПРИ РАКЕ
EP2788500A1 (de) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identifizierung von non-respondern auf her2-inhibitoren
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
WO2014083178A1 (en) 2012-11-30 2014-06-05 F. Hoffmann-La Roche Ag Identification of patients in need of pd-l1 inhibitor cotherapy
EP3454863A1 (de) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Kombinationstherapien zur behandlung von krebs
CN116745324A (zh) 2021-01-27 2023-09-12 信达生物制药(苏州)有限公司 针对cd16a的单域抗体及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
ES2070172T3 (es) 1988-04-16 1995-06-01 Celltech Ltd Procedimiento para producir proteinas mediante adn recombinante.
AU3693389A (en) 1988-05-23 1989-12-12 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Cloned gene for expression of antibodies reacting with human ovarian cancer
JP2761543B2 (ja) 1988-08-17 1998-06-04 味の素株式会社 ヒト癌原遺伝子産物に対するモノクローナル抗体及びそれを産生するハイブリドーマ
CA1341351C (en) * 1988-09-06 2002-03-26 Marc D. Better Production of chimeric mouse-human antibodies with specificity to human tumor antigens
DK0474727T3 (da) * 1989-05-19 1998-01-12 Genentech Inc HER2 ekstracellulært domæne
ATE247168T1 (de) * 1991-03-06 2003-08-15 Merck Patent Gmbh Humanisierte monoklonale antikörper
CA2096417C (en) * 1991-08-22 2000-10-10 Sarah S. Bacus Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741444B2 (en) 2002-07-04 2010-06-22 Patrys Limited Neoplasm specific antibodies and uses thereof
US8562995B2 (en) 2003-03-14 2013-10-22 Patrys Limited Neoplasm specific antibodies and uses thereof
US8124080B2 (en) 2003-11-14 2012-02-28 Patrys Limited Human monoclonal antibody having fat-reducing effect
US8741296B2 (en) 2003-11-14 2014-06-03 Patrys Limited Adenocarcinoma specific antibody SAM-6, and uses thereof
US9273125B2 (en) 2003-11-14 2016-03-01 Patrys Limited Human monoclonal antibody having fat-reducing effect

Also Published As

Publication number Publication date
JPH05192183A (ja) 1993-08-03
JP3415171B2 (ja) 2003-06-09
IE920361A1 (en) 1992-08-12
DE69212671D1 (de) 1996-09-19
AU662311B2 (en) 1995-08-31
DK0502812T3 (da) 1996-09-02
CA2060544C (en) 2002-12-03
IE72959B1 (en) 1997-05-07
ES2091438T3 (es) 1996-11-01
ATE141329T1 (de) 1996-08-15
GR3020809T3 (en) 1996-11-30
AU1042192A (en) 1992-08-13
EP0502812B1 (de) 1996-08-14
EP0502812A1 (de) 1992-09-09
CA2060544A1 (en) 1992-08-06

Similar Documents

Publication Publication Date Title
DE69212671D1 (de) Rekombinante Antikörper spezifisch für einen Wachstumsfaktor-Rezeptor
ATE366747T1 (de) Menschliche monoklonale antikörper gegen den epidermalen wachstumsfaktorrezeptor
IL93118A0 (en) Expression vectors,cells transformed thereby and their use in the production of chimeric monoclonal antibodies
ATE504601T1 (de) Anti-cd3-antikörper zur verwendung zur induzierung von immunsuppression
HU9402823D0 (en) Monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
DE3687736D1 (de) Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.
ATE316137T1 (de) Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor
MX9201016A (es) Anticuerpos monoclonales humanizados y quimericos
DE69724428D1 (de) Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren
ATE166883T1 (de) Monoklonale antikörper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
ZA9210006B (en) Anti-human IgE monoclonal antibodies.
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
CY1107163T1 (el) Συνδεδεμενα με γαγγλιοζιτη ανασυνδυασμενα αντισωματα και η χρησιμοποιηση αυτων στη διαγνωση και θεραπευτικη αγωγη ογκων

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS AG, BASEL, CH

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

8339 Ceased/non-payment of the annual fee